KalVista (NASDAQ: KALV) deregisters S-3 securities after merger

Rhea-AI Filing Summary

KalVista Pharmaceuticals, Inc. filed Post-Effective Amendment No. 1 to its Form S-3 to deregister any securities remaining unsold under Registration No. 333-280759. The amendment states KalVista completed a merger on June 11, 2026 with Skyline Merger Sub, Inc., making KalVista a wholly owned subsidiary of Chiesi Farmaceutici S.p.A.

The amendment removes from registration all securities that remained unsold or unissued under the Registration Statement and terminates the Registration Statement’s effectiveness. The filing references the Merger Agreement dated April 29, 2026 and attaches that agreement as an exhibit to a prior Form 8-K.

Insights

Corporate Finance Analyst

Post-effective amendment cleans up registration after a completed acquisition.

The filing deregisters remaining unsold securities from Registration No. 333-280759 following the Merger completed on June 11, 2026. This is an administrative step that reflects the change in corporate status to a wholly owned subsidiary of Chiesi Farmaceutici S.p.A..

Cash‑flow treatment and proceeds allocation are not stated in this excerpt; subsequent filings or the Merger Agreement provide financing and consideration details.

M&A / Securities Counsel

The amendment effectuates the contractual undertaking to remove unsold registered securities upon closing.

The document cites the Merger Agreement dated April 29, 2026 and confirms the Merger closed on June 11, 2026, making KalVista a wholly owned subsidiary of Chiesi. It expressly terminates the Registration Statement’s effectiveness and removes registered but unsold securities.

Legal implications are routine: the company fulfilled its undertaking to deregister; the Merger Agreement is the operative contract and is attached as Exhibit 2.1 to an earlier Form 8-K.

Key Figures

Registration Number: 333-280759 Merger Agreement date: April 29, 2026 Merger closing date: June 11, 2026 +1 more

4 metrics

Registration Number 333-280759 Form S-3 Post-Effective Amendment No.1

Merger Agreement date April 29, 2026 date of Merger Agreement with Chiesi and Skyline Merger Sub

Merger closing date June 11, 2026 date KalVista completed merger and became a wholly owned subsidiary of Chiesi

I.R.S. Employer ID No. 20-0915291 KalVista Pharmaceuticals, Inc. EIN stated on cover page

Key Terms

Post-Effective Amendment, Form S-3, Registration Statement

3 terms

Post-Effective Amendment regulatory

"This Post-Effective Amendment No. 1 (this “Post-Effective Amendment”) relates to the following Registration Statement"

A post-effective amendment is an official update to a securities registration document filed after that document has become effective with regulators; it corrects, adds or replaces information about the securities, the company, or an offering. Investors care because it keeps the legal record current and can change what is being sold or the rights attached to shares — like getting a revised product manual after a launch that may affect value or use.

Form S-3 regulatory

"POST-EFFECTIVE AMENDMENT NO. 1 FORM S-3 REGISTRATION STATEMENT NO. 333-280759"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

Registration Statement regulatory

"KalVista hereby removes from registration all such securities registered pursuant to the Registration Statement"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 06/11/2026 - 04:47 PM Accepted by SEC EDGAR 06/11/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What did KalVista (KALV) deregister with Post-Effective Amendment No. 1?

KalVista deregistered all securities that remained unsold or unissued under Registration No. 333-280759. The amendment states the Registration Statement is terminated and those securities are removed from registration following the Merger.

When did KalVista complete the merger that triggered the deregistration?

KalVista completed the merger on June 11, 2026. The filing ties the deregistration to the Merger whereby Skyline Merger Sub merged into KalVista, making KalVista a wholly owned subsidiary of Chiesi Farmaceutici S.p.A.

Which agreement governs the transaction described in the amendment?

The Merger Agreement dated April 29, 2026 governs the transaction. The filing states the Merger Agreement is attached as Exhibit 2.1 to KalVista’s Form 8-K filed on April 29, 2026.

Does the amendment state who receives merger consideration or use of proceeds?

The amendment does not state merger consideration or use of proceeds. It focuses on deregistering unsold securities and terminating the Registration Statement; financial consideration details are in the Merger Agreement and related filings.

As filed with the Securities and Exchange Commission on June 11, 2026

Registration No. 333-280759

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

POST-EFFECTIVE AMENDMENT NO. 1 TO

FORM S-3

REGISTRATION STATEMENT NO. 333-280759

UNDER

THE SECURITIES ACT OF 1933

KALVISTA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		20-0915291
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

200 Crossing Boulevard

(857) 999-0075

Framingham, Massachusetts 01702

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

John Hess

Chairman of the Board; President; General Manager

KalVista Pharmaceuticals, Inc.

One Boston Place, Suite 4000

Boston, Massachusetts 02108

(888) 466-6505

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Zachary Blume

Ropes & Gray LLP

800 Boylston Street, Prudential Tower

Boston, MA 02199

Telephone: (617) 951-7000

Approximate date of commencement of proposed sale to the public: Not applicable.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer		☐		Accelerated filer		☐
Non-accelerated filer		☒		Smaller reporting company		☒
				Emerging growth company		☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

DEREGISTRATION OF SECURITIES

This Post-Effective Amendment No. 1 (this “Post-Effective Amendment”) relates to the following Registration Statement on Form S-3 (the “Registration Statement”), which was previously filed by KalVista Pharmaceuticals, Inc., a Delaware corporation (“KalVista” or the “Registrant”), with the U.S. Securities and Exchange Commission (the “SEC”) and is being filed to deregister any and all securities that remain unsold or otherwise unissued as of the date hereof under such Registration Statement:

1. Registration Statement on Form S-3 (File No. 333-280759) filed with the SEC on July 11, 2024, registering KalVista’s common stock or preferred stock, debt securities, warrants to purchase KalVista’s common stock, preferred stock or debt securities, and subscription rights to purchase KalVista’s common stock, preferred stock or debt securities and/or units consisting of some or all of these securities, in any combination, having an initial aggregate offering price of up to $300,000,000.

On April 29, 2026, KalVista entered into a Merger Agreement with Chiesi Farmaceutici S.p.A., an Italian società per azioni (“Chiesi”), Skyline Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Chiesi (“Purchaser”), and KalVista Pharmaceuticals Limited, a private limited company organized under the laws of England and Wales (the “Merger Agreement”).

On June 11, 2026, KalVista completed its merger with Purchaser pursuant to the terms of the Merger Agreement, whereby Purchaser merged with and into KalVista (the “Merger”), in accordance with the General Corporation Law of the State of Delaware, with KalVista continuing as the surviving corporation and as a wholly owned subsidiary of Chiesi. As a result of the Merger, KalVista has terminated any and all offerings of its securities pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statement.

In accordance with undertakings made by KalVista in the Registration Statement to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance under the Registration Statement that remain unsold at the termination of the offerings, KalVista hereby removes from registration all such securities registered pursuant to the Registration Statement that remain unsold or otherwise unissued as of the date hereof. The Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities, and KalVista hereby terminates the effectiveness of the Registration Statement. After giving effect to this Post-Effective Amendment, there will be no remaining securities registered by KalVista pursuant to the Registration Statement.

The foregoing description of the Merger, the Merger Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by, the Merger Agreement, which is attached as Exhibit 2.1 to KalVista’s Current Report on Form 8-K filed with the SEC on April 29, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on June 11, 2026.

KALVISTA PHARMACEUTICALS, INC.
By:		/s/ John Hess
Name:		John Hess
Title:		Chairman of the Board; President; General Manager

No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.